+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis C Treatment - Market Analysis, Trends, and Forecasts

  • ID: 992790
  • Report
  • October 2019
  • 155 Pages
  • Global Industry Analysts, Inc
1 of 3

FEATURED COMPANIES

  • Abbvie
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Kadmon Holdings, Inc.
  • MORE
The Hepatitis C Treatment market worldwide is projected to grow by US$44.5 Billion, driven by a compounded growth of 12.9%. HCV Protease Inhibitors, one of the segments analyzed and sized in this study, displays the potential to grow at over 11.2%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$8.9 Billion by the year 2025, HCV Protease Inhibitors will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 11.5% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$1.8 Billion to the region's size and clout in the next 5 to 6 years. Over US$1.5 Billion worth of projected demand in the region will come from the rest of the European markets. In Japan, HCV Protease Inhibitors will reach a market size of US$176.5 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.2% over the next couple of years and add approximately US$10.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:
  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Kadmon Holdings, Inc.
  • Merck & Co., Inc.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbvie
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Kadmon Holdings, Inc.
  • MORE

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Global Competitor Market Shares

Hepatitis C Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: Hepatitis C Treatment Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 2: Hepatitis C Treatment Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017

TABLE 3: Hepatitis C Treatment Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025

TABLE 4: HCV Protease Inhibitors (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 5: HCV Protease Inhibitors (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 6: HCV Protease Inhibitors (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 7: HCV Polymerase Inhibitors (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025

TABLE 8: HCV Polymerase Inhibitors (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017

TABLE 9: HCV Polymerase Inhibitors (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

TABLE 10: HCV NS5A Inhibitors (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025

TABLE 11: HCV NS5A Inhibitors (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017

TABLE 12: HCV NS5A Inhibitors (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

TABLE 13: Combination Therapy (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025

TABLE 14: Combination Therapy (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017

TABLE 15: Combination Therapy (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025

TABLE 16: Interferon & Antiviral (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 17: Interferon & Antiviral (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 18: Interferon & Antiviral (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US Hepatitis C Treatment Market Share (in %) by Company: 2019 & 2025

TABLE 19: United States Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 20: Hepatitis C Treatment Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 21: United States Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

CANADA

TABLE 22: Canadian Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 23: Canadian Hepatitis C Treatment Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 24: Hepatitis C Treatment Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

JAPAN

TABLE 25: Japanese Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 26: Hepatitis C Treatment Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 27: Japanese Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

CHINA

TABLE 28: Chinese Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 29: Hepatitis C Treatment Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017

TABLE 30: Chinese Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

EUROPE

Market Facts & Figures

European Hepatitis C Treatment Market: Competitor Market Share Scenario (in %) for 2019 & 2025

TABLE 31: European Hepatitis C Treatment Market Demand Scenario in US$ Million by Region/Country: 2018-2025

TABLE 32: Hepatitis C Treatment Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017

TABLE 33: European Hepatitis C Treatment Market Share Shift by Region/Country: 2009 VS 2019 VS 2025

TABLE 34: European Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 35: Hepatitis C Treatment Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 36: European Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

FRANCE

TABLE 37: Hepatitis C Treatment Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 38: French Hepatitis C Treatment Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 39: French Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

GERMANY

TABLE 40: Hepatitis C Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 41: German Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 42: German Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

ITALY

TABLE 43: Italian Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 44: Hepatitis C Treatment Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017

TABLE 45: Italian Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED KINGDOM

TABLE 46: United Kingdom Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 47: Hepatitis C Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 48: United Kingdom Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

SPAIN

TABLE 49: Spanish Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 50: Spanish Hepatitis C Treatment Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 51: Hepatitis C Treatment Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

RUSSIA

TABLE 52: Russian Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 53: Hepatitis C Treatment Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 54: Russian Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

REST OF EUROPE

TABLE 55: Rest of Europe Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 56: Hepatitis C Treatment Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 57: Rest of Europe Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

ASIA-PACIFIC

TABLE 58: Asia-Pacific Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 59: Hepatitis C Treatment Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017

TABLE 60: Asia-Pacific Hepatitis C Treatment Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025

TABLE 61: Hepatitis C Treatment Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 62: Asia-Pacific Hepatitis C Treatment Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 63: Asia-Pacific Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

AUSTRALIA

TABLE 64: Hepatitis C Treatment Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 65: Australian Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 66: Australian Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

INDIA

TABLE 67: Indian Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 68: Indian Hepatitis C Treatment Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 69: Hepatitis C Treatment Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

SOUTH KOREA

TABLE 70: Hepatitis C Treatment Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 71: South Korean Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 72: Hepatitis C Treatment Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025

REST OF ASIA-PACIFIC

TABLE 73: Rest of Asia-Pacific Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 74: Hepatitis C Treatment Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 75: Rest of Asia-Pacific Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

LATIN AMERICA

TABLE 76: Latin American Hepatitis C Treatment Market Trends by Region/Country in US$ Million: 2018-2025

TABLE 77: Hepatitis C Treatment Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017

TABLE 78: Latin American Hepatitis C Treatment Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025

TABLE 79: Latin American Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 80: Hepatitis C Treatment Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017

TABLE 81: Latin American Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

ARGENTINA

TABLE 82: Argentinean Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 83: Hepatitis C Treatment Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 84: Argentinean Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

BRAZIL

TABLE 85: Hepatitis C Treatment Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 86: Brazilian Hepatitis C Treatment Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 87: Brazilian Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

MEXICO

TABLE 88: Hepatitis C Treatment Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 89: Mexican Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 90: Mexican Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

REST OF LATIN AMERICA

TABLE 91: Rest of Latin America Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 92: Hepatitis C Treatment Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 93: Rest of Latin America Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

MIDDLE EAST

TABLE 94: The Middle East Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 95: Hepatitis C Treatment Market in the Middle East by Region/Country in US$ Million: 2009-2017

TABLE 96: The Middle East Hepatitis C Treatment Market Share Breakdown by Region/Country: 2009, 2019, and 2025

TABLE 97: The Middle East Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 98: The Middle East Hepatitis C Treatment Historic Market by Drug Class in US$ Million: 2009-2017

TABLE 99: Hepatitis C Treatment Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

IRAN

TABLE 100: Iranian Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 101: Hepatitis C Treatment Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 102: Iranian Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

ISRAEL

TABLE 103: Israeli Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 104: Hepatitis C Treatment Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 105: Israeli Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

SAUDI ARABIA

TABLE 106: Saudi Arabian Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 107: Hepatitis C Treatment Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017

TABLE 108: Saudi Arabian Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED ARAB EMIRATES

TABLE 109: Hepatitis C Treatment Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 110: United Arab Emirates Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 111: Hepatitis C Treatment Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025

REST OF MIDDLE EAST

TABLE 112: Hepatitis C Treatment Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 113: Rest of Middle East Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 114: Rest of Middle East Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

AFRICA

TABLE 115: African Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 116: Hepatitis C Treatment Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 117: African Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBVIE

BRISTOL-MYERS SQUIBB COMPANY

F. HOFFMANN-LA ROCHE AG

GILEAD SCIENCES

GLAXOSMITHKLINE PLC

JOHNSON & JOHNSON

KADMON HOLDINGS, INC.

MERCK & CO., INC.

V. CURATED RESEARCH

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbvie
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Kadmon Holdings, Inc.
  • Merck & Co., Inc.
Note: Product cover images may vary from those shown
Adroll
adroll